低危前列腺癌雄激素剥夺治疗使用的全国趋势与预测因素
该研究基于美国国家癌症数据库197,957例低危前列腺癌患者(2004-2012年),发现ADT使用率从17.6%降至3.5%,但2012年近距离放疗和体外放疗患者中仍有11.5%和7.6%接受ADT;社区中心、地区差异和近距离放疗是ADT使用的预测因素,未接受局部治疗者原发ADT与全因死亡率升高相关。
要点
- 低危前列腺癌ADT使用率从2004年17.6%降至2012年3.5%,但放疗患者中仍存在不合理使用。
- 社区中心、南部/中西部/东北部地区及近距离放疗是ADT使用的独立预测因素。
- 未接受局部治疗者原发ADT与全因死亡率升高相关(aHR 1.28)。
核心结论
- 低危前列腺癌ADT使用在全国范围内下降,但在特定人群和地区仍值得关注。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列研究,纳入197,957例2004-2012年诊断的低危前列腺癌患者(Gleason 3+3=6、PSA<10 ng/mL、cT1-T2a),信息完整。
主要发现
- 总体ADT使用率从2004年17.6%降至2012年3.5%;2012年近距离放疗和体外放疗患者中ADT使用率分别为11.5%和7.6%。
- 82,352例放疗患者中,社区中心 vs 学术中心ADT使用AOR 1.60(95%CI 1.50-1.71,P<.001;2012年发生率14.0% vs 6.0%)。
- 放疗患者中,南部(AOR 1.51)、中西部(AOR 1.81)、东北部(AOR 1.90) vs 西部(P<.001)及近距离放疗 vs 体外放疗(AOR 1.32,95%CI 1.27-1.37,P<.001)预测ADT使用。
- 25,196例未接受局部治疗者中,Charlson-Deyo评分≥2 vs 0(AOR 1.42,95%CI 1.06-1.91,P=.018)、社区中心 vs 学术中心(AOR 1.61,95%CI 1.37-1.90,P<.001)及南部(AOR 1.26)、中西部(AOR 1.52)、东北部(AOR 1.28) vs 西部(P≤.008)预测原发ADT使用。
- 未接受局部治疗者中,原发ADT与全因死亡率升高相关(校正年龄和合并症后aHR 1.28,95%CI 1.14-1.43,P<.001)。
临床怎么用
- 低危前列腺癌应避免常规使用ADT,尤其放疗患者中需关注社区中心和特定地区的使用模式。
- 对未接受局部治疗的低危患者,原发ADT可能与生存受损相关,应谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Androgen deprivation therapy (ADT) is not recommended for low-risk prostate cancer because of its lack of benefit and potential for harm. We evaluated the incidence and predictors of ADT use in low-risk disease. METHODS AND MATERIALS: Using the National Cancer Database, we identified 197,957 patients with low-risk prostate cancer (Gleason score of 3 + 3 = 6, prostate-specific antigen level <10 ng/mL, and cT1-T2a) diagnosed from 2004 to 2012 with complete demographic and treatment information. We used multiple logistic regression to evaluate predictors of ADT use and Cox regression to examine its association with all-cause mortality. RESULTS: Overall ADT use decreased from 17.6% in 2004 to 3.5% in 2012. In 2012, 11.5% of low-risk brachytherapy patients and 7.6% of external beam radiation therapy patients received ADT. Among 82,352 irradiation-managed patients, predictors of ADT use included treatment in a community versus academic cancer program (adjusted odds ratio [AOR], 1.60; 95% confidence interval [CI], 1.50-1.71; P<.001; incidence, 14.0% vs 6.0% in 2012); treatment in the South (AOR, 1.51), Midwest (AOR, 1.81), or Northeast (AOR, 1.90) versus West (P<.001); and brachytherapy use versus external beam radiation therapy (AOR, 1.32; 95% CI, 1.27-1.37; P<.001). Among 25,196 patients who did not receive local therapy, predictors of primary ADT use included a Charlson-Deyo comorbidity score of ≥2 versus 0 (AOR, 1.42; 95% CI, 1.06-1.91; P=.018); treatment in a community versus academic cancer program (AOR, 1.61; 95% CI, 1.37-1.90; P<.001); and treatment in the South (AOR, 1.26), Midwest (AOR, 1.52), or Northeast (AOR, 1.28) versus West (P≤.008). Primary ADT use was associated with increased all-cause mortality in patients who did not receive local therapy (adjusted hazard ratio, 1.28; 95% CI, 1.14-1.43; P<.001) after adjustment for age and comorbidity. CONCLUSIONS: ADT use in low-risk prostate cancer has declined nationally but may remain an issue of concern in certain populations and regions.
引用
- Yang DD, Muralidhar V, Mahal BA, et al. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28463152. doi:10.1016/j.ijrobp.2017.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。